Genome wide Essential Gene Identification in Candida albicans and Applications to Antifungal Drug Discovery

Principal Investigator: Terry Roemer
Theme : Health
Competition : Competition II
Status : Completed
Start : Jan. 1, 2003
End: Mar. 31, 2007
Budget : $2,561,397.00



Fungal infections are a serious health threat to humans, particularly those with weakened immune systems. Safer and more effective antifungal drugs are needed. One of the key agents causing fungal diseases is the yeast known as Candida albicans. By studying the genome of Candida albicans, this project proposes to find all of the genes essential to the life of this fungal pathogen, thereby identifying new targets for drug therapies.

 

Co-project leader:

Bo Jiang Merck Frosst Canada Ltd.

 

Co-applicant:

Phil Youngman Merck Frosst Canada Ltd.